Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOTOMA perioperative durvalumab plus tremelimumab for resectable hepatocellular carcinoma
2023-508863-59-01Phase 2Authorised
- Sponsor
- University Health Network
- Start
- Jun 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC), sponsored by University Health Network. Primary endpoint: Severe treatment-limiting adverse events. Planned start Jun 2026; status: authorised.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-508863-59-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508863-59-01.